Is ABBV stock a Buy, Sell, or Hold?

Based on our analysis, ABBV is currently a HOLD with moderate confidence. 📊 HOLD: ABBV shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

What is the fair value of ABBV stock?

Our analysis estimates the fair value range for ABBV to be between $212.12 and $232.36. The current price is $209.40.

What is the analyst price target for ABBV?

The average Wall Street analyst price target for ABBV is $249.14. This implies a potential upside of 19.0% from current levels.

ABBV Stock Analysis: Buy, Sell, or Hold?

ABBV - ABBVIE INC.

PHARMACEUTICAL PREPARATIONS

$209.40

-1.72 (-0.81%) ▼

5d: +2.11%

30d: -6.8%

90d: -9.08%

HOLD

MODERATE Confidence

Protect Your ABBV Gains

Analysis Updated: Mar 27, 2026 12:00 AM ET

Earnings: Apr 24, 2026 24d

Smart Money Accumulation

ABBV is down 3.7% this week, but smart money is accumulating calls. Top strike: $250 2026-03-20 with 7,487 OI. Call ratio: 60% View Scanner →

Strength: 2.9/10

Get Alerted When ABBV Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: ABBV shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 10.9%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$343.49

Based on 7.4% avg growth

INTRINSIC VALUE TODAY

$213.28

1.8% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.9x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: ABBV is currently trading at $209.40, which is considered oversold relative to its 30-day fair value range of $212.12 to $232.36. From a valuation perspective, the stock is trading at a discount (Forward PE: 13.0) compared to its historical average (14.9). Remarkably, the market is currently pricing in an annual earnings decline of 4.5% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, ABBV is in a strong uptrend. Immediate support is located at $201.80, while resistance sits at $224.37.

Market Sentiment: ABBV has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $249.14 (+19.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position OVERSOLD

Fair Price Range $212.12 - $232.36

Company Quality Score 55/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 54.8%

Protect Your Profits

Holding ABBV? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Price oversold vs 30-day range
BEARISH: Weak technical setup (25/100)
BULLISH: High volume confirmation
BULLISH: Trading below Wall St target ($249.14)

Fair Price Analysis

30-Day Fair Range $212.12 - $232.36

Current vs Fair Value OVERSOLD

Support & Resistance Levels

Support Level $201.80

Resistance Level $224.37

Current Trend Strong Uptrend

Technical data as of Mar 27, 2026

Fundamental Context

Forward P/E (Next Year Est.) 12.99

Wall Street Target $249.14 (+19.0%)

Revenue Growth (YoY) 10.0%

Earnings Growth (YoY) -88.7%

Profit Margin 6.9%

Valuation Discount vs History -4.5% cheaper

PE vs Historical 13.0 vs 14.9 CHEAP

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -4.5% (market-implied from PE analysis)

1-Year Target $199.98 (-5%)

2-Year Target $190.98 (-9%)

3-Year Target $182.38 (-13%)

3-Yr Target (if PE normalizes) (PE: 13→15) $209.15 (0%)

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 22.4, Growth: 10.9%) $491.92 (+135%)

Base: (SPY PE: 13.0, Growth: 10.9%) $285.34 (+36%)

Bear: (PE: 11.0, Growth: 10.9%) $242.54 (+16%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (13x PE) as earnings recover.

Forward PE: 14.08 | Forward EPS (Implied): $14.55

Bull Case $247.45 (+21%)

Analyst growth 15.0%, PE expands to 14.8

Base Case $204.93 (0%)

Market implied 0.0%, PE stable at 14.1

Bear Case $156.77 (-24%)

Severe decline -15.0%, PE contracts to 12.7

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 13.0 to 14.9

Stabilization Target: $240.13 (+14.7%)

PE Expansion Potential: +14.7%

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: March 30, 2026 8:52 AM ET
Data refreshes hourly during market hours. Next update: 9:52 AM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is ABBV showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS SELLING

Recent Transactions

David Ryan Purdue SELL 5230 shares 2026-03-04

Perry C Siatis SELL 22381 shares 2026-02-25

Ro Khanna BUY 2026-02-05

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for ABBV.

Create Free Account

Already have an account? Log In

Featured in Portfolios

ABBV is a key holding in these high-performance investment strategies.

Healthcare Giants Sector • -7.7% Return

View All Strategies

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
LLY Eli Lilly and Company	STRONG BUY 29 analysts	$1209	51 HOLD
GILD Gilead Sciences Inc	BUY 30 analysts	$157	57 HOLD
BIIB Biogen Inc	HOLD 37 analysts	$206	62 BUY
MRK Merck & Company Inc	BUY 26 analysts	$128	68 BUY
AMGN Amgen Inc	HOLD 32 analysts	$351	58 HOLD

LLY Eli Lilly and Com…

51 HOLD

GILD Gilead Sciences I…

57 HOLD

BIIB Biogen Inc

62 BUY

MRK Merck & Company I…

68 BUY

AMGN Amgen Inc

58 HOLD

Advanced ABBV Option Strategies

Professional options setups generated by AI based on today's ABBV price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for ABBV

ABBV Technical Chart ABBV Price Prediction ABBV Earnings Date ABBV Investment Advisor ABBV Fair Price Analyzer ABBV Options Advisor ABBV Options Chain ABBV Options Analysis ABBV Competitors

Compare ABBV with Other Stocks

Create New Comparison

Tradestie